TI17 , a novel compound, exerts anti‐MM activity by impairing Trip13 function of DSBs repair and enhancing DNA damage
Cancer Medicine · 2023
DOI: 10.1002/cam4.6706 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Shuaikang Chang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Acetamides, Pyridines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program", China, Natural Science Foundation of Shanghai Municipality.
Abstract (Originalsprache)
Background
Thyroid hormone receptor interacting protein 13 (Trip13) is an AAA‐ATPase that regulates the assembly or disassembly protein complexes and mediates Double‐strand breaks (DSBs) repair. Overexpression of Trip13 has been detected in many cancers and is associated with myeloma progression, disease relapse and poor prognosis inmultiple myeloma (MM).
Methods
We have identified a small molecular, TI17, through a parallel compound‐centric approach, which specifically targets Trip13. To identify whether TI17 targeted Trip13, pull‐down and nuclear magnetic resonance spectroscopy (NMR) assays were performed. Cell counting kit‐8, clone formation, apoptosis and cell cycle assays were applied to investigate the effects of TI17. We also utilized a mouse model to investigate the effects of TI17 in vivo.
Results
TI17 effectively inhibited the proliferation of MM cells, and induced the cycle arrest and apoptosis of MM cells. Furthermore, treatment with TI17 abrogates tumor growth and has no apparent side effects in mouse xenograft models. TI17 specifically impaired Trip13 function of DSBs repair and enhanced DNA damage responses in MM. Combining with melphalan or HDAC inhibitor panobinostat triggers synergistic anti‐MM effect.
Conclusions
Our study suggests that TI17 could be acted as a specific inhibitor of Trip13 and supports a preclinical proof of concept for therapeutic targeting of Trip13 in MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
- Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
- State Key Laboratory of Drug Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
ORCID-Profile: Jumei Shi
Förderung
- National Natural Science Foundation of China
- National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program", China
- Natural Science Foundation of Shanghai Municipality
- Shanghai Sailing Program
Zitieren
APA
Chang, S., Xiao, W., Xie, Y., Xu, Z., Li, B., Wang, G., Hu, K., Zhang, Y., Zhou, J., Song, D., Zhu, H., Wu, X., Lu, Y., Shi, J., & Zhu, W. (2023). TI17 , a novel compound, exerts anti‐MM activity by impairing Trip13 function of DSBs repair and enhancing DNA damage. Cancer Medicine. https://doi.org/10.1002/cam4.6706
Vancouver
Chang S, Xiao W, Xie Y, Xu Z, Li B, Wang G, et al. TI17 , a novel compound, exerts anti‐MM activity by impairing Trip13 function of DSBs repair and enhancing DNA damage. Cancer Medicine. 2023. doi:10.1002/cam4.6706
BibTeX
@article{Chang2023,
author = {Chang, Shuaikang and Xiao, Wenqin and Xie, Yongsheng and Xu, Zhijian and Li, Bo and Wang, Guanli and Hu, Ke and Zhang, Yong and Zhou, Jinfeng and Song, Dongliang and Zhu, Huabin and Wu, Xiaosong and Lu, Yumeng and Shi, Jumei and Zhu, Weiliang},
title = {TI17 , a novel compound, exerts anti‐MM activity by impairing Trip13 function of DSBs repair and enhancing DNA damage},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6706}
}
EUVIMED